ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGON vs KOD // EV/EBITDA & P/E VALUATION

CG Oncology Inc. (NASDAQ) VS. Kodiak Sciences Inc (NASDAQ) • 15-METRIC TALLY: CGON 8 — KOD 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. KOD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGON KOD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.80% -35.00% +14.20 CGON /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -2.35% -2.16% -0.19 KOD /fcf-yield <GO>
Operating Margin -12.10% -13.30% +1.20 CGON /operating-margins <GO>
Net Profit Margin -10.20% -13.00% +2.80 CGON /net-margins <GO>
Revenue Growth (YoY) 8.80% 1.10% +7.70 CGON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 16.70 +9.30 CGON /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 CGON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.5 63.0 -21.50 KOD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.07 0.90 +0.17 CGON /macro-sensitivity <GO>
Forward P/E Multiple 20.0x 35.0x -15.00 CGON /forward-pe <GO>
Enterprise Scale & Market Cap $5.49B $6.14B -$643.5M KOD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGON REV KOD REV CGON GROSS % KOD GROSS % CGON FCF KOD FCF
FY 2025 $534.2M $656.3M — — -$132.5M -$136.5M
FY 2024 $321.1M $523.2M — — -$78.9M -$117.7M
FY 2023 $155.3M $776.5M — — -$45.7M -$154.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
KOD // BETA 0.90